Skip to main content
Advertising

Originally published Monday, March 5, 2012 at 10:41 AM

  • Share:
             
  • Comments ((0))
  • Print

Summary Box: FDA won't approve Merck drug for now

NO GO: The Food and Drug Administration won't OK Merck's new combo cholesterol drug without more data. Merck says new data on compound MK-0653C, expected later this year, may address FDA questions.

The Associated Press

Comments
No comments have been posted to this article.

advertising

NO GO: The Food and Drug Administration won't OK Merck's new combo cholesterol drug without more data. Merck says new data on compound MK-0653C, expected later this year, may address FDA questions.

LIPITOR LURE?: The experimental drug combines Merck cholesterol pill Zetia with generic Lipitor, which had been the top-selling drug ever but got generic competition three months ago.

NEW AND IMPROVED: Merck already sells Vytorin, a cholesterol pill that combines Zetia with generic Zocor, a Merck drug similar to but not as strong as Lipitor. The new combo might work better than Vytorin.

News where, when and how you want it

Email Icon

 Subscribe today!

Subscribe today!

99¢ for four weeks of unlimited digital access.

Advertising

Advertising

NDN Video

Advertising